Trending

#AVTX

Latest posts tagged with #AVTX on Bluesky

Latest Top
Trending
#Canada's Politics #Spurs #Liverpool FC #Oscars #Ukraine Conflict #U.S. Foreign Policy #F1 #Chinese Grand Prix #SNL #Venezuela Baseball #Canada's Politics #Spurs #Liverpool FC #Oscars #Ukraine Conflict #U.S. Foreign Policy #F1 #Chinese Grand Prix #SNL #Venezuela Baseball

Posts tagged #AVTX

StockTitan
StockTitan
@stocktitan.net
4 months ago
Preview
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Avalo Therapeutics (NASDAQ: AVTX) completed enrollment in its Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa (~250 adults) and expects topline data in mid-2026. The company appointed Kevin Lind to the board and added senior leaders in business development and HR. As of September 30, 2025, cash, cash equivalents and short-term investments totaled approximately $111.6 million, which the company said is expected to fund operations into 2028. For Q3 2025, R&D was $13.6M, G&A was $5.6M, and net loss was $30.6M (basic loss per share $2.19).

#AVTX Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

www.stocktitan.net/news/AVTX/avalo-therapeu...

0 0 0 0
StockTitan
StockTitan
@stocktitan.net
4 months ago
Preview
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa Avalo Therapeutics (Nasdaq: AVTX) announced completion of enrollment in its Phase 2 LOTUS trial of AVTX-009 for adults with hidradenitis suppurativa (HS).The trial exceeded its target of 222 patients with approximately 250 patients enrolled. LOTUS is a randomized, double-blind, placebo-controlled Phase 2 study (1:1:1) testing two AVTX-009 dose regimens versus placebo during a 16-week treatment phase. The primary endpoint is the proportion achieving HiSCR75 at Week 16. Secondary measures include HiSCR50/90, IHS4, draining fistula count, AN count, and PGA Skin Pain reductions. Topline data are expected in mid-2026. Trial identifiers: NCT06603077 and www.lotustrial.com.

#AVTX Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

www.stocktitan.net/news/AVTX/avalo-therapeu...

0 0 0 0
Nasdaq
Nasdaq
@nasdaq.activitypub.awakari.com.ap.brid.gy
5 months ago
Preview
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Avalo Therapeutics (NASDAQ:AVTX) Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS ) rose sharply in today's pre-market trading . Genmab announced plans to acquire...

#AVTX #BIAF #CGC #CLLS #CYCU #ENTA #ENTA #EPOW #JFB #LRMR #MLTX

Origin | Interest | Match

0 0 0 0
StockTitan
StockTitan
@stocktitan.net
7 months ago
Preview
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.

#AVTX Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

www.stocktitan.net/news/AVTX/avalo-reports-...

0 0 0 0
StockTitan
StockTitan
@stocktitan.net
10 months ago
Preview
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Avalo Therapeutics (NASDAQ: AVTX) reported its Q1 2025 financial results and business updates. The company ended Q1 with $125 million in cash, providing runway into 2027 with potential extension into 2028. The Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) is progressing as planned, with topline data expected in 2026.Q1 2025 financial highlights include: net loss of $13.1 million ($1.25 per share), R&D expenses of $9.1 million (up $7.0M YoY), and G&A expenses of $5.5 million (up $2.4M YoY). The company is carefully evaluating the timing of additional development activities beyond LOTUS trial due to current market conditions. [ "Strong cash position of $125M providing runway into 2027, with potential extension to 2028", "Phase 2 LOTUS trial enrollment progressing on schedule with topline data expected in 2026", "Significant reduction in net loss to $13.1M in Q1 2025 from $121.3M in Q1 2024" ]

#AVTX Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

www.stocktitan.net/news/AVTX/avalo-reports-...

0 0 0 0
StockTitan
StockTitan
@stocktitan.net
11 months ago
Preview
Avalo Secures 3-Year Cash Runway with $134.5M, Pushes Forward Phase 2 Trial Avalo strengthens financial position with $185M placement, extending runway to 2027. Phase 2 LOTUS trial in hidradenitis suppurativa progresses with new strategic leadership.

#AVTX Avalo Reports 2024 Financial Results and Recent Business Updates

www.stocktitan.net/news/AVTX/avalo-reports-...

0 0 0 0
Market Wire News
Market Wire News
@marketwirenews.com
1 year ago

NEWS: ( NASDAQ: #AVTX ) Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

#StockMarket #News

0 0 0 0